Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

737 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD8 T-cell recognition of human 5T4 oncofetal antigen.
Smyth LJ, Elkord E, Taher TE, Jiang HR, Burt DJ, Clayton A, van Veelen PA, de Ru A, Ossendorp F, Melief CJ, Drijfhout JW, Dermime S, Hawkins RE, Stern PL. Smyth LJ, et al. Among authors: clayton a. Int J Cancer. 2006 Oct 1;119(7):1638-47. doi: 10.1002/ijc.22018. Int J Cancer. 2006. PMID: 16646078
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE, Savage KI, Lioe T, Boyd C, Halliday S, Walker SM, Lowry K, Knight L, Buckley NE, Grogan A, Logan GE, Clayton A, Hurwitz J, Kirk SJ, Xu J, Sidi FA, Humphries MP, Bingham V; Neo-DDIR Investigators; James JA, James CR, Paul Harkin D, Kennedy RD, McIntosh SA. Parkes EE, et al. Among authors: clayton a. Br J Cancer. 2022 Feb;126(2):247-258. doi: 10.1038/s41416-021-01599-0. Epub 2021 Nov 2. Br J Cancer. 2022. PMID: 34728791 Free PMC article.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators. Brown JE, et al. Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796394 Free article. Clinical Trial.
Development and Evaluation of an Automated Multimodal Mobile Detection of Oral Cancer (mDOC) Imaging System to Aid in Risk-based Management of Oral Mucosal Lesions.
Mitbander R, Brenes D, Coole JB, Kortum A, Vohra IS, Carns J, Schwarz RA, Varghese I, Durab S, Anderson S, Bass NE, Clayton AD, Badaoui H, Anandasivam L, Giese RA, Gillenwater AM, Vigneswaran N, Richards-Kortum R. Mitbander R, et al. Among authors: clayton ad. Cancer Prev Res (Phila). 2025 Jan 16. doi: 10.1158/1940-6207.CAPR-24-0253. Online ahead of print. Cancer Prev Res (Phila). 2025. PMID: 39817650
The impact of common and rare genetic variants on bradyarrhythmia development.
Weng LC, Rämö JT, Jurgens SJ, Khurshid S, Chaffin M, Hall AW, Morrill VN, Wang X, Nauffal V, Sun YV, Beer D, Lee S, Nadkarni GN, Duong T, Wang B, Czuba T, Austin TR, Yoneda ZT, Friedman DJ, Clayton A, Hyman MC, Judy RL, Skanes AC, Orland KM, Treu TM, Oetjens MT, Alonso A, Soliman EZ, Lin H, Lunetta KL, van der Pals J, Issa TZ, Nafissi NA, May HT, Leong-Sit P, Roselli C, Choi SH; FinnGen; Million Veteran Program; Regeneron Genetics Center; Khan HR, Knight S, Karlsson Linnér R, Bezzina CR, Ripatti S, Heckbert SR, Gaziano JM, Loos RJF, Psaty BM, Smith JG, Benjamin EJ, Arking DE, Rader DJ, Shah SH, Roden DM, Damrauer SM, Eckhardt LL, Roberts JD, Cutler MJ, Shoemaker MB, Haggerty CM, Cho K, Palotie A, Wilson PWF, Ellinor PT, Lubitz SA. Weng LC, et al. Among authors: clayton a. Nat Genet. 2025 Jan;57(1):53-64. doi: 10.1038/s41588-024-01978-2. Epub 2025 Jan 2. Nat Genet. 2025. PMID: 39747593 Free PMC article.
737 results